Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug development

Scientists find another link between aspirin and cancer treatment

Research suggests that combining immunotherapy with aspirin, a COX inhibitor, can slow cancer growth in mice.

Research suggests that combining immunotherapy with aspirin, a COX inhibitor, can slow cancer growth in mice. In the image, melanoma cells

Source: National Cancer Institute

Researchers have found that some tumour cells (melanoma, in picture) can produce significant levels of a molecule called prostaglandin E2 (PGE2), which can dampen the immune system’s normal response to attack faulty cells

A study by UK researchers has found a possible explanation for a reported link between aspirin and a reduced risk of cancer. It also points to novel disease biomarkers and a useful addition to the arsenal of conventional and immune-based cancer therapies. 

Caetano Reis e Sousa at the Francis Crick Institute in London and colleagues have found that some tumour cells produce significant levels of a molecule called prostaglandin E2 (PGE2). PGE2 is produced by the enzyme cyclooxygenase (COX) and dampens the immune system’s normal response employed to attack faulty cells. 

The research was based primarily on mouse melanoma, but the research team also looked at human melanoma biopsies and found that the COX-dependent inflammatory signature was markedly similar in mice and men, suggesting that this is a highly conserved response. Based on this, Reis e Sousa’s team argues that COX activity is a driver of immune suppression across species. 

Tumour cells that produce sufficient PGE2 are able to evade a patient’s immune defences. Many immunotherapies used to treat cancer, which are designed to boost the patient’s own immune response to fight off tumour cells, are not as effective as might be expected. Reis e Sousa’s team suggests this could be attributed to tumour cells producing increased PGE2 and fighting off even this therapeutically-amplified immune response. Knowing which tumour cells produce sufficient levels of PGE2 to thwart immune defence could help clinicians predict which tumours will respond favourably, and which will not, to a given immunotherapy. 

Aspirin, a COX inhibitor, is known to stop the production of PGE2 and help boost the immune system. Reis e Sousa’s team found that putting aspirin in the drinking water of mice had no effect on melanoma cells that had been implanted in the mice. However, when it was combined with an immunotherapy (anti-PD-1 monoclonal antibody), tumour cells were eradicated much more quickly than with immunotherapy alone. 

“These findings have obvious therapeutic implications,” writes Reis e Sousa in Cell[1] on 3 September 2015. Treating patients with aspirin alongside immunotherapy could make a huge difference to the benefits associated with treatment, he says. “It’s early work but this could help make cancer immunotherapy even more effective.” 

In 2013, a US research group at Stanford University School of Medicine discovered that women who took aspirin on a regular basis reduced their risk of developing melanoma. 

“We don’t know how much aspirin should be taken, or for how long, to be most effective,” said lead researcher, Jean Tang, at the time. She was also mindful of the well-known side effects of aspirin use — stomach complaints, ulcers and bleeding. “Our aim is to find a drug or agent that is readily available, and that will be well-tolerated, safe to use and protective against cancer development,” said Tang. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069289

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Research suggests that combining immunotherapy with aspirin, a COX inhibitor, can slow cancer growth in mice. In the image, melanoma cells

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.